Obsessive Compulsive Disorder Clinical Trial
— SC-CBTNCT number | NCT01981317 |
Other study ID # | IOCDF2013 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | October 2013 |
Est. completion date | October 2018 |
Verified date | October 2018 |
Source | University of South Florida |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this research study is to determine how well children with OCD can be helped using therapy that requires less clinic visits. The investigators are testing a Stepped-Care Cognitive Behavioral Therapy (SC-CBT) approach in which children receive a full course of parent-led, therapist-guided treatment for OCD. The goal is to see if therapy can be done in fewer visits to the clinic. Children receiving SC-CBT will start with Step One, which includes three therapy sessions over six weeks. Those who do not get better in Step One will "STEP UP" to Step Two which involves coming in to meet with a therapist for the remaining sessions. Youth receiving SC-CBT will be compared to youth receiving standard CBT in the clinic through this study. It is expected that Stepped Care will be an acceptable, cost-effect, and feasible treatment with outcomes similar to standard CBT.
Status | Completed |
Enrollment | 30 |
Est. completion date | October 2018 |
Est. primary completion date | March 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 8 Years to 17 Years |
Eligibility |
Inclusion Criteria: - Outpatient youth with obsessive-compulsive disorder between the ages 8-17 years. - A Children's Yale-Brown Obsessive-Compulsive Scale score = 16 - Child has a Full Scale IQ = 80 as assessed on the WASI - English speaking Exclusion Criteria: - Past adequate CBT with E/RP trial - Initiation of antidepressant medication within 12 weeks before study enrollment, or an antipsychotic/mood stabilizer medication 6 weeks before study enrollment, or a stimulant/anxiolytic or alpha 2 agonist 4 weeks before study enrollment - Established Treatment changes: Any change in dose of an established psychotropic medication (e.g., antidepressants) within 8 weeks before study enrollment (4 weeks for antipsychotic, mood stabilizer, alpha 2 agonist; 2 weeks for stimulant/anxiolytic). Alternative medications must be stable for 4 weeks prior to baseline. Any medications must remain stable during treatment; downward adjustments due to side effects may be acceptable with PI approval. - Active child suicidality assessed by all available information (e.g., KSADS-PL, CDI). - DSM-IV conduct disorder, autism, mental retardation, bipolar, schizophrenia/schizoaffective disorders; or substance abuse in past 6 months; or co-primary eating disorder; using all available information. - Another behavioral/emotional problem or psychiatric disorder is considered to be more problematic than OCD. - Non-English speaking. - WASI-IQ SS <80. |
Country | Name | City | State |
---|---|---|---|
United States | The Rothman Center for Pediatric Neuropsychiatry | Saint Petersburg | Florida |
Lead Sponsor | Collaborator |
---|---|
University of South Florida | Obsessive Compulsive Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Children's Yale-Brown Obsessive-Compulsive Scale | The Children's Yale-Brown Obsessive-Compulsive Scale is a psychometrically sound clinician-rated interview assessing OCD symptom severity. | 12 weeks | |
Primary | Clinical Global Impression Improvement Scale | The CGI-I is a widely used 7-point clinician rating of clinical improvement. | 12 weeks | |
Secondary | Clinical Global Impression Severity Scale | The CGI-S is a widely used 7-point clinician rating of clinical severity. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04631042 -
Developing Brain, Impulsivity and Compulsivity
|
||
Completed |
NCT02855580 -
Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic
|
||
Completed |
NCT02229903 -
An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD
|
N/A | |
Completed |
NCT02202915 -
CBT for Pediatric OCD: Community Training Pilot
|
N/A | |
Completed |
NCT01794156 -
Evaluation of a Cognitive Therapy (Inference-based-therapy) for the Treatment of Obsessional Compulsive Disorder
|
N/A | |
Completed |
NCT02089984 -
Web Based Therapist Training on Cognitive Behavior Therapy for Anxiety Disorders
|
N/A | |
Completed |
NCT01348529 -
Internet Cognitive Behavior Therapy (CBT) for Obsessive Compulsive Disorder (OCD)
|
N/A | |
Recruiting |
NCT00965211 -
Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome
|
N/A | |
Completed |
NCT00723060 -
Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder
|
Phase 4 | |
Not yet recruiting |
NCT00743834 -
Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD)
|
Phase 4 | |
Completed |
NCT01172873 -
D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD
|
N/A | |
Completed |
NCT02421315 -
Overlapping Neural Circuits in Pediatric OCD
|
N/A | |
Completed |
NCT02194075 -
Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder
|
Phase 4 | |
Completed |
NCT01686087 -
Attaining and Maintaining Wellness in Obsessive-compulsive Disorder
|
N/A | |
Terminated |
NCT00997087 -
A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder
|
Phase 2 | |
Completed |
NCT01331876 -
Modification of Cerebral Activity of Obsessive Compulsive Disorder (OCD) Patients During Cognitive and Behavioral Therapy
|
N/A | |
Completed |
NCT00533806 -
Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder
|
Phase 3 | |
Completed |
NCT00517244 -
Evaluating Parenting Styles and Child Temperament Associated With Child Anxiety Disorders
|
N/A | |
Completed |
NCT00169377 -
Subthalamic Nucleus (STN) Stimulation and Obsessive-Compulsive Disorder (OCD)
|
Phase 1/Phase 2 | |
Completed |
NCT00116532 -
Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD)
|
Phase 4 |